Skip to content
Search resources Open menu

Adult-CERT

Drug-Facilitated Sexual Assault: Toxicology, Detection Limits, and What the Results Can Show

Published

Snap Shot

  • The question: When a complainant believes she or he was drugged before a sexual assault, what can toxicology testing show, and what can it not show?
  • What the research shows: In case series from North America, Europe, and Australia, alcohol, usually consumed voluntarily and often at high levels, and cannabis are the substances found most often (cannabis slightly more often in the largest recent U.S. laboratory series), followed by cocaine, amphetamines, and prescription drugs. Covert administration is confirmed in a minority of suspected cases, and estimates vary with definition (an unadmitted sedative or disinhibiting drug in 2% of 1,014 London cases; no case unequivocally attributable among 264 Trondheim patients; 32% classed as probable covert administration in a Paris series of 100 that included non-sexual crimes). Detection is limited by short half-lives (GHB plasma half-life about 0.5 to 0.9 hours), delayed sampling, cut-offs for substances the body produces naturally, and laboratory scope.
  • What it does not show: A negative screen means a substance was not detected in that specimen, at that time, by that method; it does not show that no drug was given. A positive screen does not show who gave the drug, when, whether it was taken knowingly, or how impaired the person was at the time of the act. The research has not been shown to tell a court whether a particular person was drugged or assaulted.
  • The law: Article 120(a)(5), UCMJ, and 18 U.S.C. § 2241(b)(2) require proof that the accused administered a substance by force, threat, or without the person’s knowledge or consent (permission, in the federal statute); Article 120(b)(3)(A) and A.R.S. § 13-1401(A)(7)(b) turn on incapacity from any source. Arizona raises the sentencing range by three years under A.R.S. § 13-1406(B) only for covert administration of flunitrazepam, GHB, or ketamine. Smith v. Arizona (2024) limits how a substitute analyst may relay an absent analyst’s work.
  • Issues for each side: Prosecutors should collect specimens early, document the complainant’s own intake, call the analyst who did the work, and avoid presenting a negative screen as meaningless or a positive one as proof of drugging; defense counsel should distinguish presence from administration and timing, test the laboratory’s scope and the confrontation record, and avoid presenting a negative screen as proof that no drug was given.

Drug-facilitated sexual assault, meaning a sexual act committed while a person is impaired by alcohol or another drug, is a serious and well-documented offense. Sexual assault is common and substantially underreported; about one in four rape and sexual assault victimizations were reported to police in 2024 (23.6%), an estimate that has varied considerably from year to year (46.0% in 2023; Tapp & Coen, 2025), and drug- or alcohol-involved rapes are reported less often than forcible rapes (Wolitzky-Taylor et al., 2011). Among 314 undergraduate women, 29.6% reported a drug- or alcohol-related sexual assault or rape and 5.4% a forcible one (Lawyer et al., 2010).

Typically, a complainant reports a loss of memory or control out of proportion to what she or he drank and suspects a spiked drink, and toxicology collected hours or days later becomes contested. Prosecutors may need to explain why a negative result does not mean no drug was given; defense counsel may need to explain why a positive result does not show who gave it or when.

This paper reviews the toxicology case series, drink-spiking research, specific substances, detection limits, and what results can mean, then federal, military, and Arizona law, including confrontation rules for laboratory evidence. Alcohol’s effects on memory and capacity, voluntary intoxication, and mistake of fact are addressed in Alcohol, Blackouts, and Memory in Sexual Assault Cases.

Defining Drug-Facilitated Sexual Assault: Proactive and Opportunistic

In proactive (or predatory) drug-facilitated sexual assault, the offender covertly or forcibly gives the person a drug (“chemical submission”); in opportunistic drug-facilitated sexual assault, the offender takes advantage of impairment from substances taken voluntarily (“chemical vulnerability”) (Djezzar et al., 2023). Both can be criminal, the law treats them differently, and definitions drive the figures. In Ontario, 48.9% of 178 tested cases of suspected drugging were classed as predatory because a drug was found that the person had not reported taking (Du Mont et al., 2016). In a U.S. study at four clinics, 43% of 144 participants, or 7% of all 859 clinic complainants in the period, were classified as drug-facilitated under a definition that included voluntary intoxication (Juhascik et al., 2007). European studies requiring an unexplained sedative and corroborated history report much lower rates; a percentage without its definition is incomplete.

What Toxicology Studies Find

The largest series find alcohol and cannabis most often. In a U.S. series of 1,179 urine samples submitted where drugging was suspected, 468 were negative for every substance tested; 451 were positive for ethanol, 218 for cannabinoids, 97 for a cocaine metabolite, 97 for benzodiazepines, and 48 for GHB (ElSohly & Salamone, 1999). Two decades later, among 1,000 suspected U.S. cases, 21.6% were negative; ethanol was found in 30.9%, cannabinoids in 28.8%, amphetamine or methamphetamine in 16.5%, cocaine in 10.4%, and clonazepam in 7.6%, and the authors noted that negative results may reflect delayed collection (Fiorentin & Logan, 2019). The cases came from 37 states and one U.S. territory; among the 309 with a blood ethanol result, the mean was 98.6 mg/dL (about 0.099 g/dL) and the median 82.0 mg/dL (about 0.082 g/dL), with a range of 9.2 to 366 mg/dL (Fiorentin & Logan, 2019). The abstract does not report how long after the event the specimens were collected, these are concentrations in submitted specimens and not estimates of the person’s concentration at the time of the event, and no concentration is a cutoff for impairment or incapacity. In the largest recent series, 2,371 blood and 5,041 urine samples submitted to the same reference laboratory in drug-facilitated crime cases from 2019 to 2023, THC or its metabolites were the most prevalent finding in both specimens, followed closely by ethanol and then stimulants, and GHB and flunitrazepam were infrequent (Hessler et al., 2025). Both U.S. series include crimes other than sexual assault, and a cannabis result may reflect use well before the event. Most complainants in these series are women: 91.7% of the 613 cases with sex recorded in the 1,000-case series (Fiorentin & Logan, 2019) and 90.1% of cases with sex recorded from 2019 to 2023 (Hessler et al., 2025).

Other countries show the same pattern. In London, 1,014 cases from 2000 to 2002 showed alcohol in 46% and illicit drugs in 34% (cannabis 26%, cocaine 11%); in 21 cases (2%) a sedative or disinhibiting drug was found that the complainant had not admitted taking, which the authors said could indicate deliberate spiking, and in another 1% the complainant had been given or forced to take drugs (Scott-Ham & Burton, 2005). In Victoria, Australia, unreported drugs were found in 20% of 76 suspected cases (3% of all 434 adult cases) after a median 20-hour delay, and the authors cautioned that the true rate could be higher or lower (Hurley et al., 2006).

Among 264 female patients aged 12 and older at a Trondheim center, 22% suspected proactive drugging, but only five had sedative findings not explained by their reported intake, no case could be attributed unequivocally to proactive drugging, and GHB was never found (Hagemann et al., 2013). In 369 police-reported sexual assault cases from Eastern Denmark, toxicology was positive in 86%, most often for alcohol (45%) and drugs of abuse (38%), and the authors judged most cases opportunistic (Skov et al., 2023). Among 643 females aged 15 and older examined at a Copenhagen center from 2021 to 2023, under a definition that included voluntary intoxication, ethanol, cocaine, and THC were the most frequent substances, and drug-facilitated cases more often involved younger complainants, weekends, nights, and a perpetrator first met that day (Rasmussen et al., 2026). The best-controlled design to date, from Stockholm, screened urine collected within 48 hours for more than 100 relevant substances and added a control sample and standardized intake history 10 to 14 days later; of 31 women who completed it (of 55 who presented), 97% reported voluntary alcohol intake, unexpected findings occurred in five (16%), most often cocaine, and no typical “date-rape drug” was found where involuntary intake was considered likely (Möller et al., 2025).

French data point in a different direction. A Paris study of 100 patients who reported suspected covert drugging to police classed 32% as probable proactive cases after clinical correlation; 90% had voluntarily consumed ethanol beforehand (Liautard et al., 2024). A 19-year French national survey of 5,487 drug-facilitated crimes classified 17% as proven chemical submission and 29% as chemical vulnerability; in the proven cases, benzodiazepines and Z-drugs (such as zolpidem) accounted for 55% of substances, other sedatives including antihistamines 16%, and GHB 4%, while alcohol (90%) and cannabis (32%) dominated the vulnerability cases (Djezzar et al., 2023). Both French studies included crimes other than sexual assault, and the national survey included child victims; 81% of its victims were female (Djezzar et al., 2023).

A systematic review of adult studies concluded that, aside from alcohol, no drug category was specifically associated with drug-facilitated sexual assault and that voluntary alcohol and drug use present the greatest risk, despite popular perceptions of common covert spiking (Anderson et al., 2017). The proactive rate thus ranges from none confirmed to roughly half, depending on definition, analytic scope, delay, and whether “unexpected” is measured against self-report alone or a corroborated history.

Perceived and Confirmed Drink Spiking

Belief in having been drugged is common. Among 6,064 students at three U.S. universities, 7.8% reported having been drugged, describing 539 incidents, and 1.4% said they had drugged someone or knew someone who had; the study had no toxicological confirmation (Swan et al., 2017). Emergency department studies usually found heavy intoxication and few unexplained drugs. In inner-city London, 60% of 78 patients had serum ethanol above 1.5 g/L, drugs of unexplained origin were found in 10%, and unexplained sedatives in 3% (Greene et al., 2007); in Wales, 65% of tested patients had alcohol above 160 mg per 100 mL (Hughes et al., 2007). In an Australian study of 97 cases, nine were judged plausible, none showed a sedative likely placed in a drink at a pub or club, and 35% of patients still believed they had been spiked after receiving results (Quigley et al., 2009). In Oslo, among 100 patients tested a median of five hours after suspected exposure, unreported drugs (including clonazepam, MDMA, and amphetamine) were found in 15% and GHB in none (Dalaker et al., 2024). That sample included 38 men, and unreported drugs were found in 7 men and 8 women, numbers too small for a sex comparison.

Many people who believe they were drugged have alcohol concentrations that could account for their symptoms, and severe intoxication and sedatives produce overlapping symptoms, so the belief alone is not evidence of drugging. Yet unreported drugs are found in a real minority of tested cases, testing was limited in scope and timing, and a belief that persists after a negative result is not shown to be wrong by that result.

Specific Substances

GHB (gamma-hydroxybutyrate), the substance most associated with spiking in public discussion, is detected infrequently in most series: 1.1% of unexpected drugs in Ontario (Du Mont et al., 2010), 4% of proven French cases (Djezzar et al., 2023), infrequently in the largest recent U.S. laboratory series (Hessler et al., 2025), and never in Trondheim or Oslo (Hagemann et al., 2013; Dalaker et al., 2024). Prompt sampling can change the picture. In a Paris study that tested 49 adults for GHB a mean of 6.0 hours after suspected covert drugging, six had GHB in urine (three also in blood) and none of the six reported taking it, often in a chemsex context; the authors judged 11 cases probable proactive and 17 opportunistic (Dubois et al., 2026). The sample was small and concerned drug-facilitated crime generally. Low detection rates are consistent with infrequent use and also with a detection problem, because GHB has a plasma half-life of about 0.5 to 0.9 hours and only 1% to 2% of a dose is excreted unchanged in urine (Busardò & Jones, 2019). The data cannot separate the two explanations.

Beyond the French proven cases (Djezzar et al., 2023), clonazepam appeared in the U.S. series and among unreported drugs in Oslo (Fiorentin & Logan, 2019; Dalaker et al., 2024). Designer benzodiazepines, potent, often short-lived, and constantly changing, challenge standard panels (Pérez Orts et al., 2023). Ketamine is rare (2.3% of unexpected drugs in Ontario; Du Mont et al., 2010), and flunitrazepam is excluded from the U.S. urine testing standard because of its limited availability in the United States (AAFS Standards Board, 2021). Cannabis metabolites persist in urine, so a positive result often reflects earlier use, and antihistamines and antidepressants, often prescribed, require a medication history to interpret (Skov et al., 2023).

Detection Windows, Specimens, and Laboratory Scope

Delay before collection often decides what can be found. In a Northern Ireland series, 44% to 74% of cases each year were sampled more than 12 hours after the alleged assault, and the authors noted that some negative results may be false negatives (Hall et al., 2008). The U.S. standard for urine testing in drug-facilitated crime investigations requires testing of urine collected within 120 hours, but not ethanol testing after 24 hours or GHB testing after 12 hours, and sets minimum sensitivities (for example, 10 µg/mL for GHB); it does not cover blood (AAFS Standards Board, 2021). The national protocol for sexual assault medical forensic examinations issued by the Department of Justice’s Office on Violence Against Women advises collecting urine if less than 120 hours have elapsed since the incident (urine being the preferred specimen), and says blood may prove useful if collected less than 24 hours afterward, since most drugs are undetectable in blood more than 24 hours after ingestion (U.S. Department of Justice, Office on Violence Against Women, 2024). The protocol is guidance for collecting specimens in the examination; the standard above governs the analytical scope and sensitivity of the urine testing. A laboratory’s panel may be narrower. Specimen choice matters too: in the largest recent U.S. series, urine identified substances in 22% of cases with negative blood results (Hessler et al., 2025).

GHB illustrates how specimen handling matters. Because the body produces small amounts of GHB and concentrations can rise after collection, laboratories use cut-offs to avoid false positives (Busardò & Jones, 2019). One study found endogenous concentrations up to 4.20 mg/L in urine and proposed lowering the urine cut-off from 10 mg/L to 6 mg/L to avoid false negatives (Andresen et al., 2010). In a placebo-controlled trial in 30 volunteers, endogenous blood GHB did not exceed 0.050 µg/mL in fluoride-oxalate tubes cooled immediately, and a blood cut-off of 0.25 µg/mL extended the blood detection window by at least two hours, beyond that of urine at a 6 µg/mL cut-off (Faldborg et al., 2025). The window depends on specimen, tube, storage, and cut-off as well as the drug.

Hair can extend the window. One review recommended collecting hair about one month after the event, noting very low single-dose concentrations and the need for more data before legally defensible cut-offs exist (Kintz, 2007). Hair color, growth rate, sample preparation, and surface contamination affect interpretation of segmental results (Xiang et al., 2015), and a six-year French compendium of 22 cases (complainants aged 13 to 47) found hair positive in 41% while noting that interpretive reference data remain scarce (Fort et al., 2026).

What a Negative or a Positive Result Means

A negative result means that the substances tested for were not found above the laboratory’s cut-offs in the specimen received. It does not establish that no drug was given: the drug may have cleared, been off the panel, been below the cut-off, or been masked by endogenous levels. Nor does it suggest that a drug was given; the same result occurs when none was. A negative result after prompt collection with a broad, sensitive panel carries more weight than one after delay with a narrow panel.

A positive result shows that a substance was present. It does not show who gave it, when, or whether the person took it knowingly. Some complainants in a four-locality U.S. study had underreported their own drug use (Juhascik et al., 2007), and Ontario researchers who classed drugs as “unexpected” by comparison with self-report found mostly cannabinoids (40.2%) and cocaine (32.2%); they read the frequent unexpected drugs, with unexpected male DNA in 46.9% of DNA-positive cases, as support for complainants’ accounts (Du Mont et al., 2010), while underreported voluntary use could produce the same toxicology finding. Nor does it establish impairment at the time of the act; a later concentration must be related back through assumptions about dose, timing, and metabolism, and for urine and hair that relationship is weak. Sex is one of those assumptions for alcohol: women generally reach higher blood alcohol concentrations than men from the same dose, even adjusted for body weight (Mumenthaler et al., 1999). Alcohol back-calculation is discussed in Retrograde Extrapolation and the Limits of the Widmark Formula in the Alcohol Blackouts resource.

Limits of the Evidence

The case series are laboratory or clinic samples of people who reported and were tested, not random samples of assaults, with incomplete histories, varying delays, and analytic methods that differ across countries and decades. Whether intake was voluntary is usually inferred from self-report, which may be incomplete in either direction. Several series include adolescents, the French data include non-sexual crimes, and drink-spiking surveys measure belief, not confirmed exposure. Most tested complainants are women, several series enrolled only women (Hagemann et al., 2013; Möller et al., 2025; Rasmussen et al., 2026), and male cases are too few to show how often men are covertly drugged; in the largest U.S. series, 71% of male and 79% of female cases were positive for at least one substance, without a test of the difference (Hessler et al., 2025). A chart review of 45 men who received a medical forensic examination identified tactical administration of alcohol and drugs as a recurring theme (Oesterle et al., 2024), and assaults of men are addressed in the paper on male complainants and sexual assault in military settings.

Most fundamentally, no study has been shown to tell a court whether a particular person was drugged, whether an assault occurred, or whether the person could consent. Toxicology answers a narrower question, whether a substance was detected in a specimen. An expert may explain detection windows, cut-offs, and when a result is more or less informative, but cannot properly testify, from toxicology alone, that a negative result shows no drug was given or that a positive result shows covert drugging.

Questions to Ask About This Research

When the 48.9% “predatory” figure (Du Mont et al., 2016) is cited, ask what exactly was counted: a drug not reported, measured against self-report alone. When the London 2% (Scott-Ham & Burton, 2005) or Stockholm 16% (Möller et al., 2025) figure is offered to show that covert drugging is rare, ask whether the conclusion follows from the design, given delay, panel scope, short half-lives, and Stockholm’s 31 completers. When Quigley et al. (2009) is cited for persisting belief, ask how much evidence it rests on: 97 cases in one emergency department. When a GHB result is offered either way, ask what specimen, storage, and cut-off were used (Faldborg et al., 2025). These questions are explained in “Reading Research Claims: A Guide for Attorneys” on this site.

Drug-Facilitated Sexual Assault and the Law

Federal and Military Standards

The law separates administration offenses from incapacity offenses. Article 120(a)(5), UCMJ, defines rape to include a sexual act committed by administering to the other person, by force or threat of force, or without that person’s knowledge or consent, a drug, intoxicant, or other similar substance, thereby substantially impairing the person’s ability to appraise or control conduct. The 2024 Manual for Courts-Martial prints that text, but its sample specification still reads “without the knowledge or permission,” the wording of pre-2019 versions; the statute controls. Article 120(b)(3)(A), by contrast, covers a sexual act with a person incapable of consenting (defined in Article 120(g)(8)) due to impairment by any drug, intoxicant, or other similar substance, when the accused knows or reasonably should know of that condition. Under (a)(5), the prosecution must prove that the accused administered the substance, a question toxicology bears on only indirectly because a result shows presence, not who gave the substance; under (b)(3)(A), the source of impairment, including voluntary drinking, does not matter, but incapacity and actual or constructive knowledge must be proved. United States v. Mendoza (2024), United States v. Casillas (2025), and United States v. Moore (2026), which treat lack of consent and incapacity as separate theories, are discussed in the companion alcohol paper. Executive Order 14130 (Dec. 20, 2024) did not amend paragraph 60 on Article 120, including the sample specification.

The federal civilian counterpart, 18 U.S.C. § 2241(b)(2), which applies in the special maritime and territorial jurisdiction and federal prisons, punishes by any term of years or life knowingly administering a drug or intoxicant by force or threat, or without the person’s knowledge or permission, thereby substantially impairing the person’s ability to appraise or control conduct, and then engaging in a sexual act. Separately, 21 U.S.C. § 841(b)(7), added by the Drug-Induced Rape Prevention and Punishment Act of 1996, punishes distributing a controlled substance to a person without that person’s knowledge with intent to commit a crime of violence, including rape. Reported decisions are few. United States v. Lopez (4th Cir. 2017) (unpublished) affirmed a § 2241(b)(2) conviction of a Veterans Affairs medical center nurse who gave a woman seeking care morphine over her repeated refusals; the court found administration without permission shown by her testimony that she refused the drug. In United States v. Palmer (A.F. Ct. Crim. App. 2013) (unpublished), decided under an earlier version of Article 120, the court found factually sufficient a conviction for rape by administering GHB without the victim’s knowledge or permission, relying on a toxicologist’s testimony that the victim’s urine was positive for GHB, the accused’s recently filled prescription for sodium oxybate (pharmaceutical GHB), and SANE and DNA evidence.

Toxicology evidence also raises confrontation questions. Testimonial statements of an absent declarant require unavailability and a prior opportunity for cross-examination (Crawford v. Washington, 2004); sworn certificates of drug analysis are testimonial (Melendez-Diaz v. Massachusetts, 2009); and a certified blood-alcohol report cannot come in through a surrogate analyst who neither performed nor observed the test (Bullcoming v. New Mexico, 2011). In Smith v. Arizona (2024), arising from an Arizona Department of Public Safety drug analysis, the Court held that when an expert conveys an absent analyst’s statements in support of the expert’s opinion, and the statements support that opinion only if true, they are offered for their truth; labeling them basis evidence does not avoid the Confrontation Clause. The Court left for remand whether the statements were testimonial, and noted that an expert may still testify from personal knowledge about the laboratory’s general practices, about general forensic principles, and to hypotheticals whose assumed facts are separately proved. Confrontation, Child Hearsay, and Remote Testimony, in the Child Abuse Allegations resource, applies Smith to experts who relay a child’s statements.

Military courts addressed drug-laboratory evidence before Smith. United States v. Blazier (C.A.A.F. 2010) held urinalysis cover memoranda prepared for court-martial use testimonial and, in a second opinion, held that an expert may rely on testimonial hearsay but may not serve as a conduit for it, and that cross-examining that expert does not substitute for confronting the analysts. United States v. Sweeney (C.A.A.F. 2011) required statement-by-statement review of drug-testing reports, held the cover memorandum and specimen-custody certifications testimonial, and treated an objection not made at a pre-Melendez-Diaz trial as forfeited rather than waived. United States v. Katso (C.A.A.F. 2015), a sexual assault case, held that a DNA examiner who had performed the technical review and reached his own conclusions was neither a surrogate nor a mere conduit. After Smith, the Navy-Marine Corps Court of Criminal Appeals, in a published urinalysis case, held that a substitute expert’s testimony about cocaine-metabolite urinalysis results, from samples the expert had not tested, was not plain Confrontation Clause error under Smith and that any error was harmless (United States v. Dillenburger, 2025); an unpublished decision followed it (United States v. Coleman, 2025). Whether Katso‘s reasoning survives Smith has been raised in pending petitions, and current authority should be checked.

Expert testimony is governed by Military Rule of Evidence 702 (printed in the 2024 MCM in its pre-December 2023 form; the 2023 federal amendment’s status under Military Rule 1102 is discussed in the companion admissibility paper) and the Houser factors. Military Rule 703 permits disclosing inadmissible basis facts to members only if their probative value in evaluating the opinion substantially outweighs their prejudicial effect; after Smith, that rule does not resolve the confrontation question. Under R.C.M. 703(d), the military judge decides whether a defense expert witness’s testimony is relevant and necessary or a consultant’s assistance is necessary for an adequate defense; a request naming the specific toxicology question is better positioned than a general one.

Arizona

Arizona sexual assault requires intentional or knowing sexual intercourse or oral sexual contact without consent (A.R.S. § 13-1406(A)). “Without consent” includes circumstances in which the victim is incapable of consent by reason of mental disorder, mental defect, drugs, alcohol, sleep, or any other similar impairment of cognition and the condition is known or should have reasonably been known to the defendant (A.R.S. § 13-1401(A)(7)(b)); the listed circumstances are not exhaustive (State v. Witwer, 1993). The jury instruction (RAJI (Criminal) 14.06.01) also requires that the defendant knew the act was without consent (citing State v. Kemper, 2011); how that element operates alongside the “should have reasonably been known” standard for incapacity is not resolved in the authorities cited here. In State v. Johnson (1987), where the prosecution relied on both intoxication and mental disorder and the evidence of mental disorder was insufficient, the court reversed because the general verdict might have rested on the unsupported theory.

Arizona’s sexual assault statute has one provision specific to drugging. Under A.R.S. § 13-1406(B), if the sexual assault involved the intentional or knowing administration of flunitrazepam, gamma hydroxy butyrate, or ketamine hydrochloride without the victim’s knowledge, the presumptive, minimum, and maximum sentences increase by three years. The jury decides the allegation after a guilty verdict, unanimously, beyond a reasonable doubt, on a separate verdict form (RAJI (Criminal) 14.06.02). Other benzodiazepines, Z-drugs, and antihistamines, the substances most often confirmed in the French covert-administration series, are not listed; their covert administration would be addressed through the general “without consent” definitions. Because a named drug must be identified, GHB’s short detection window and laboratory scope bear directly on proof of the enhancement.

Smith v. Arizona rejected the not-for-the-truth reasoning Arizona courts had applied under State ex rel. Montgomery v. Karp (App. 2014). Expert testimony is governed by Arizona Rule of Evidence 702 and State v. Salazar-Mercado (2014).

Special Issues in Legal Practice

The principles described above apply with equal force to every party in a legal proceeding. The science operates the same way regardless of who is asking the questions, and the research summarized here does not by itself favor either side. What differs between the parties is not the science but the vantage point — the particular places where these issues tend to surface, and the particular errors each party may need to guard against. The two summaries below identify those recurring issues. They are offered for orientation, not as litigation strategy; in every case the controlling question is what the evidence in that case will, and will not, support, and the expert’s role is to inform the trier of fact rather than to advocate for either side.

Special Issues for Prosecutors

The research supports several propositions prosecutors can legitimately present. A negative result is common after delay, with a limited panel, or with a short half-life, and an expert can explain as general education why it does not show that no drug was given (Hall et al., 2008; Busardò & Jones, 2019). Because voluntarily consumed alcohol and drugs dominate nearly every series, the evidence in many cases bears more on incapacity under Article 120(b)(3)(A) or A.R.S. § 13-1401(A)(7)(b) than on administration, which toxicology rarely confirms, and Mendoza shows that the theory charged must match the proof. Prompt blood (in properly handled tubes) and urine collection, hair about a month later, and a complete history of the complainant’s own intake strengthen what toxicology can show (Kintz, 2007; Faldborg et al., 2025), and complainants’ own drug use may be underreported (Juhascik et al., 2007). Under Smith, calling the analyst who did the work is least likely to produce reversible error; a substitute’s testimony should stay with laboratory practices, general principles, or properly founded hypotheticals, and Dillenburger shows what survived plain-error review, not what is safe at trial.

The research also counsels caution. A negative result is consistent with either administration or no administration, and testimony presenting it as uninformative in every case overstates the point when collection was prompt and the panel broad. A complainant’s belief that she or he was drugged does not by itself establish drugging, although it is a report a factfinder may weigh with other evidence, and testimony that symptoms indicate a particular drug is not supported, because severe alcohol intoxication produces overlapping effects (Greene et al., 2007; Hughes et al., 2007). The Arizona enhancement requires a unanimous jury finding that one of three named drugs was administered, which a general “date-rape drug” theory will not satisfy.

Special Issues for Defense

The research supports several propositions defense counsel can legitimately present. A positive result shows presence, not administration, timing, or impairment at the time of the act; cannabis metabolites persist, hair results are difficult to interpret (Xiang et al., 2015; Fort et al., 2026), and “unexpected” findings measured against self-report may reflect underreported voluntary use (Juhascik et al., 2007). Administration charges under Article 120(a)(5), § 2241(b)(2), and the Arizona enhancement require proof that someone gave the drug. Requests for the laboratory’s scope, cut-offs, and limits of detection, and a specific R.C.M. 703(d) showing for expert assistance, are grounded in the science. Smith, Blazier, and Sweeney support a timely confrontation objection when a substitute relays an absent analyst’s work; Dillenburger and Sweeney show that an objection not made at trial may be reviewed only for plain error or lost.

The research also counsels caution about the defense’s own inferences. A negative screen does not show that no drug was given, particularly after delay or with a narrow panel; presenting it that way is the overstatement the defense would object to from the other side. Unreported drugs were found in a real minority of drink-spiking cases, and a complainant’s belief does not become inaccurate because testing was negative. Voluntary intoxication can still support an incapacity charge, so showing that no drug was administered does not answer an incapacity theory.

This paper is for educational purposes only and is not legal advice. The author is a psychologist, not an attorney; summaries of law are general and must be verified against current authority or with a licensed attorney.

References

AAFS Standards Board. (2021). Standard for the analytical scope and sensitivity of forensic toxicological testing of urine in drug-facilitated crime investigations (ANSI/ASB Standard 121, 1st ed.). American Academy of Forensic Sciences. https://www.aafs.org/sites/default/files/media/documents/121_Std_e1.pdf

Anderson, L. J., Flynn, A., & Pilgrim, J. L. (2017). A global epidemiological perspective on the toxicology of drug-facilitated sexual assault: A systematic review. Journal of Forensic and Legal Medicine, 47, 46–54. https://doi.org/10.1016/j.jflm.2017.02.005

Andresen, H., Sprys, N., Schmoldt, A., Mueller, A., & Iwersen-Bergmann, S. (2010). Gamma-hydroxybutyrate in urine and serum: Additional data supporting current cut-off recommendations. Forensic Science International, 200(1–3), 93–99. https://doi.org/10.1016/j.forsciint.2010.03.035

Busardò, F. P., & Jones, A. W. (2019). Interpreting γ-hydroxybutyrate concentrations for clinical and forensic purposes. Clinical Toxicology, 57(3), 149–163. https://doi.org/10.1080/15563650.2018.1519194

Dalaker, V. M., Furuhaugen, H., Brekke, M., Bjørnaas, M. A., Krpo, M., Øiestad, E. L., & Vallersnes, O. M. (2024). Drugs in blood and urine samples from victims of suspected exposure to drink spiking: A prospective observational study from Oslo, Norway. PLOS ONE, 19(7), Article e0306191. https://doi.org/10.1371/journal.pone.0306191

Djezzar, S., Gaulier, J. M., Gorgiard, C., Chèze, M., Alvarez, J. C., Martin, C., Dumestre-Toulet, V., Lavit, M., Mathieu, O., Eysseric, H., Berland, E., Roussel, C., Gaillard, Y., Hurtel-Lemaire, A. S., Deveaux, M., & Pion, C. (2023). Assessment of 19 years of a prospective national survey on drug-facilitated crimes in France. Legal Medicine, 65, Article 102297. https://doi.org/10.1016/j.legalmed.2023.102297

Du Mont, J., Macdonald, S., & Kosa, D. (2016). An examination of victim, assailant, and assault characteristics among cases classified as predatory drug-facilitated sexual assault. Women’s Health Issues, 26(4), 393–400. https://doi.org/10.1016/j.whi.2016.05.010

Du Mont, J., Macdonald, S., Rotbard, N., Bainbridge, D., Asllani, E., Smith, N., & Cohen, M. M. (2010). Drug-facilitated sexual assault in Ontario, Canada: Toxicological and DNA findings. Journal of Forensic and Legal Medicine, 17(6), 333–338. https://doi.org/10.1016/j.jflm.2010.05.004

Dubois, L., Magny, R., Labat, L., Augustin, C., Pinto, T., Truchot, J., Liautard, M., Houzé, P., & Dufayet, L. (2026). Implication of GHB in proactive drug facilitated crime in Paris, France. Forensic Science International, 378, Article 112734. https://doi.org/10.1016/j.forsciint.2025.112734

ElSohly, M. A., & Salamone, S. J. (1999). Prevalence of drugs used in cases of alleged sexual assault. Journal of Analytical Toxicology, 23(3), 141–146. https://doi.org/10.1093/jat/23.3.141

Faldborg, K. B., Sørensen, L. K., Hasselstrøm, J. B., & Andersen, C. U. (2025). Endogenous levels, detection time, and symptoms of gamma-hydroxybutyric acid: Results from a placebo-controlled clinical trial. Basic & Clinical Pharmacology & Toxicology, 137(6), Article e70133. https://doi.org/10.1111/bcpt.70133

Fiorentin, T. R., & Logan, B. K. (2019). Toxicological findings in 1000 cases of suspected drug facilitated sexual assault in the United States. Journal of Forensic and Legal Medicine, 61, 56–64. https://doi.org/10.1016/j.jflm.2018.11.006

Fort, A., Boudin, C., Eysseric-Guerin, H., Scolan, V., Borges, J., Chiron, F., Henry, P., Stanke-Labesque, F., & Willeman, T. (2026). Insights from a 6-year hair drug analysis compendium in drug-facilitated sexual assault cases. Journal of Forensic Sciences, 71(4), 1783–1792. https://doi.org/10.1111/1556-4029.70331

Greene, S. L., Shiew, C. M., Streete, P., Mustchin, S. J., Hugget, D., Earl, B., & Dargan, P. I. (2007). What’s being used to spike your drink? Alleged spiked drink cases in inner city London. Postgraduate Medical Journal, 83(986), 754–758. https://doi.org/10.1136/pgmj.2007.059048

Hagemann, C. T., Helland, A., Spigset, O., Espnes, K. A., Ormstad, K., & Schei, B. (2013). Ethanol and drug findings in women consulting a Sexual Assault Center—Associations with clinical characteristics and suspicions of drug-facilitated sexual assault. Journal of Forensic and Legal Medicine, 20(6), 777–784. https://doi.org/10.1016/j.jflm.2013.05.005

Hall, J., Goodall, E. A., & Moore, T. (2008). Alleged drug facilitated sexual assault (DFSA) in Northern Ireland from 1999 to 2005: A study of blood alcohol levels. Journal of Forensic and Legal Medicine, 15(8), 497–504. https://doi.org/10.1016/j.jflm.2008.05.006

Hessler, M. R., Kacinko, S. L., & Logan, B. K. (2025). Drug-facilitated crime: A review of findings between 2019 and 2023. Journal of Forensic Sciences, 70(6), 2442–2464. https://doi.org/10.1111/1556-4029.70151

Hughes, H., Peters, R., Davies, G., & Griffiths, K. (2007). A study of patients presenting to an emergency department having had a “spiked drink.” Emergency Medicine Journal, 24(2), 89–91. https://doi.org/10.1136/emj.2006.040360

Hurley, M., Parker, H., & Wells, D. L. (2006). The epidemiology of drug facilitated sexual assault. Journal of Clinical Forensic Medicine, 13(4), 181–185. https://doi.org/10.1016/j.jcfm.2006.02.005

Juhascik, M. P., Negrusz, A., Faugno, D., Ledray, L., Greene, P., Lindner, A., Haner, B., & Gaensslen, R. E. (2007). An estimate of the proportion of drug-facilitation of sexual assault in four U.S. localities. Journal of Forensic Sciences, 52(6), 1396–1400. https://doi.org/10.1111/j.1556-4029.2007.00583.x

Kintz, P. (2007). Bioanalytical procedures for detection of chemical agents in hair in the case of drug-facilitated crimes. Analytical and Bioanalytical Chemistry, 388(7), 1467–1474. https://doi.org/10.1007/s00216-007-1209-z

Lawyer, S., Resnick, H., Bakanic, V., Burkett, T., & Kilpatrick, D. (2010). Forcible, drug-facilitated, and incapacitated rape and sexual assault among undergraduate women. Journal of American College Health, 58(5), 453–460. https://doi.org/10.1080/07448480903540515

Liautard, M., Magny, R., Houzé, P., Deguette, C., Alcaraz, E., Douaouria, S., Gorgiard, C., Labat, L., & Dufayet, L. (2024). Pro-active drug-facilitated crimes (DFC): A study in the Department of Forensic Medicine of Paris, France. International Journal of Legal Medicine, 138(2), 415–430. https://doi.org/10.1007/s00414-023-03090-2

Möller, A., Högbeck, I., Meyer, M. R., Wissenbach, D., Beck, O., & Helander, A. (2025). Toxicological findings in Swedish cases of suspected drug-facilitated sexual assault (DFSA). Scandinavian Journal of Clinical and Laboratory Investigation, 85(4), 269–274. https://doi.org/10.1080/00365513.2025.2511305

Mumenthaler, M. S., Taylor, J. L., O’Hara, R., & Yesavage, J. A. (1999). Gender differences in moderate drinking effects. Alcohol Research & Health, 23(1), 55–64.

Oesterle, D. W., McKee, G. B., Dworkin, E. R., Blackburn, A. M., Daigle, L. E., Gill-Hopple, K., & Gilmore, A. K. (2024). Characteristics of sexual assault among men receiving a forensic medical examination. Journal of Child Sexual Abuse, 33(3), 337–354. https://doi.org/10.1080/10538712.2023.2249890

Pérez Orts, M., van Asten, A., & Kohler, I. (2023). The evolution toward designer benzodiazepines in drug-facilitated sexual assault cases. Journal of Analytical Toxicology, 47(1), 1–25. https://doi.org/10.1093/jat/bkac017

Quigley, P., Lynch, D. M., Little, M., Murray, L., Lynch, A.-M., & O’Halloran, S. J. (2009). Prospective study of 101 patients with suspected drink spiking. Emergency Medicine Australasia, 21(3), 222–228. https://doi.org/10.1111/j.1742-6723.2009.01185.x

Rasmussen, M., Busch, J. R., Munkholm, J., Skov, K. Ø., Nielsen, M. K. K., Hilden, M., Banner, J., & Wingren, C. J. (2026). Characteristics of drug-facilitated sexual assault (DFSA): An observational study at a Danish sexual assault center. International Journal of Legal Medicine, 140(2), 1131–1144. https://doi.org/10.1007/s00414-025-03646-4

Scott-Ham, M., & Burton, F. C. (2005). Toxicological findings in cases of alleged drug-facilitated sexual assault in the United Kingdom over a 3-year period. Journal of Clinical Forensic Medicine, 12(4), 175–186. https://doi.org/10.1016/j.jcfm.2005.03.009

Skov, K., Johansen, S. S., Linnet, K., & Nielsen, M. K. K. (2023). Uncovering forensic evidence of drug-facilitated sexual assault: Toxicological findings from Eastern Denmark from 2015–2022. Legal Medicine, 65, Article 102325. https://doi.org/10.1016/j.legalmed.2023.102325

Swan, S. C., Lasky, N. V., Fisher, B. S., Woodbrown, V. D., Bonsu, J. E., Schramm, A. T., Warren, P. R., Coker, A. L., & Williams, C. M. (2017). Just a dare or unaware? Outcomes and motives of drugging (“drink spiking”) among students at three college campuses. Psychology of Violence, 7(2), 253–264. https://doi.org/10.1037/vio0000060

Tapp, S. N., & Coen, E. J. (2025). Criminal victimization, 2024 (NCJ 310547). U.S. Department of Justice, Bureau of Justice Statistics.

U.S. Department of Justice, Office on Violence Against Women. (2024). A national protocol for sexual assault medical forensic examinations: Adults/adolescents (3rd ed.; NCJ 228119). https://www.justice.gov/ovw/media/1367191/dl

Wolitzky-Taylor, K. B., Resnick, H. S., McCauley, J. L., Amstadter, A. B., Kilpatrick, D. G., & Ruggiero, K. J. (2011). Is reporting of rape on the rise? A comparison of women with reported versus unreported rape experiences in the National Women’s Study-Replication. Journal of Interpersonal Violence, 26(4), 807–832. https://doi.org/10.1177/0886260510365869

Xiang, P., Shen, M., & Drummer, O. H. (2015). Review: Drug concentrations in hair and their relevance in drug facilitated crimes. Journal of Forensic and Legal Medicine, 36, 126–135. https://doi.org/10.1016/j.jflm.2015.09.009

Legal Authorities

Bullcoming v. New Mexico, 564 U.S. 647 (2011).

Crawford v. Washington, 541 U.S. 36 (2004).

Melendez-Diaz v. Massachusetts, 557 U.S. 305 (2009).

Smith v. Arizona, 602 U.S. 779 (2024).

State ex rel. Montgomery v. Karp, 236 Ariz. 120, 336 P.3d 753 (App. 2014).

State v. Johnson, 155 Ariz. 23, 745 P.2d 81 (1987).

State v. Kemper, 227 Ariz. 452 (App. 2011).

State v. Salazar-Mercado, 234 Ariz. 590, 325 P.3d 996 (2014).

State v. Witwer, 175 Ariz. 305, 856 P.2d 1183 (App. 1993).

United States v. Blazier, 68 M.J. 439 (C.A.A.F. 2010).

United States v. Blazier, 69 M.J. 218 (C.A.A.F. 2010).

United States v. Casillas, 86 M.J. 94 (C.A.A.F. 2025).

United States v. Coleman, No. 202400173 (N-M. Ct. Crim. App. Oct. 30, 2025) (unpublished).

United States v. Dillenburger, 85 M.J. 599 (N-M. Ct. Crim. App. 2025) (No. 202300172, Mar. 27, 2025), rev. denied, No. 25-0174/NA (C.A.A.F. July 17, 2025).

United States v. Houser, 36 M.J. 392 (C.M.A. 1993).

United States v. Katso, 74 M.J. 273 (C.A.A.F. 2015).

United States v. Lopez, 689 F. App’x 732 (4th Cir. 2017) (per curiam) (unpublished) (No. 16-4612, May 16, 2017).

United States v. Mendoza, 85 M.J. 213 (C.A.A.F. 2024).

United States v. Moore, 86 M.J. 308 (C.A.A.F. 2026).

United States v. Palmer, ACM 38184 (A.F. Ct. Crim. App. Nov. 25, 2013) (unpublished).

United States v. Sweeney, 70 M.J. 296 (C.A.A.F. 2011).

U.S. Const. amend. VI.

10 U.S.C. § 920 (Article 120, Uniform Code of Military Justice).

18 U.S.C. § 2241(b)(2).

21 U.S.C. § 841(b)(7).

Drug-Induced Rape Prevention and Punishment Act of 1996, Pub. L. No. 104-305, 110 Stat. 3807.

Ariz. Rev. Stat. Ann. § 13-1401(A)(7)(b).

Ariz. Rev. Stat. Ann. § 13-1406(A)–(B).

Revised Arizona Jury Instructions (Criminal) 14.06.01, 14.06.02 (6th ed. 2022).

Ariz. R. Evid. 702.

Mil. R. Evid. 702, 703, 1102.

Rule for Courts-Martial 703(d).

Exec. Order No. 14130, 2024 Amendments to the Manual for Courts-Martial, United States, 89 Fed. Reg. 105343 (Dec. 27, 2024).

Related topic papers: Alcohol, Blackouts, and Memory in Sexual Assault Cases · Memory Contamination: Discussion, Interviews, and Post-Event Information · Behavioral Indicators, Base Rates, and the Limits of Inference · Admissibility of Counterintuitive Behavior Testimony · Preparing for and Examining a Counterintuitive Behavior Expert · Genital Injury, Its Absence, and the Medical Forensic Examination · Consent Communication, Misperception, and Mistake of Fact · Male Complainants and Sexual Assault in Military Settings

Related topics from Arizona Forensic Services: Alcohol Blackouts · Child Abuse Allegations · Courts-Martial